Form 4: Verona Pharma Director Vikas Sinha Acquires 240,000 Share Options
SEC Form 4
Director Vikas Sinha acquired 240,000 share options in Verona Pharma plc on April 29, 2024.
Summary
- Vikas Sinha, a director of Verona Pharma plc, acquired 240,000 share options on April 29, 2024.
- The exercise price of these options is $1.9338.
- The options vest in four equal installments, starting on July 29, 2024, and continuing quarterly until April 29, 2025.
- The options expire on April 28, 2034.
- Each American Depositary Share (ADS) represents eight ordinary shares of Verona Pharma.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of share option grants to a director. The grant itself could be seen as a positive, but the filing is simply a factual report.
Positives
- The acquisition of share options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Key Dates
| Date | Description |
|---|---|
| 04/29/2024 | Date of transaction: Vikas Sinha acquired 240,000 share options. |
| 07/29/2024 | First vesting date: 25% of the options become exercisable. |
| 10/29/2024 | Second vesting date: Another 25% of the options become exercisable. |
| 01/29/2025 | Third vesting date: Another 25% of the options become exercisable. |
| 04/29/2025 | Final vesting date: The remaining 25% of the options become exercisable. |
| 04/28/2034 | Expiration date of the share options. |
| 04/30/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.